文献速递免疫规划

通过突变IBDV VP5关键氨基酸生成新型减毒传染性法氏囊病病毒疫苗株

Generation of a novel attenuated IBDV vaccine strain by mutation of critical amino acids in IBDV VP5.
PubMed 文献 · Vaccine · 2024-06-29

本研究利用反向遗传系统对传染性法氏囊病病毒(IBDV)VP5蛋白进行氨基酸突变,构建了IBDV-VP5/3m突变株。该突变株在感染早期复制减少、延迟细胞死亡,接种鸡后减轻法氏囊损伤并诱导与亲本野生株相当的中和抗体;接种后能保护鸡抵抗中国新型变异株nVarIBDV攻击,减少法氏囊病毒载量并缓解法氏囊萎缩和脾肿大,提示其可能作为新型疫苗候选株进一步开发。

要点

  • IBDV-VP5/3m突变株在感染早期复制减少并延迟细胞死亡。
  • 接种鸡后减轻法氏囊损伤,诱导与亲本野生株相当的中和抗体。
  • 接种后保护鸡抵抗nVarIBDV攻击,减少法氏囊病毒载量并缓解法氏囊萎缩和脾肿大。

核心结论

  • IBDV-VP5/3m突变株可能作为新型疫苗候选株,有望进一步开发为临床控制传染性法氏囊病的有效疫苗。

研究设计与样本

  • 研究通过反向遗传系统构建VP5氨基酸突变的IBDV突变株,并在鸡中评估其免疫原性和保护效果。

主要发现

  • IBDV-VP5/3m突变株导致宿主细胞死亡率降低,感染早期复制减少并延迟细胞死亡。
  • 接种鸡后有效减轻法氏囊损伤,诱导的中和抗体产生与亲本IBDV野生株相当。
  • 接种后保护鸡抵抗nVarIBDV攻击,减少法氏囊中nVarIBDV载量并缓解法氏囊萎缩和脾肿大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infectious bursal disease virus (IBDV) is an acute and highly infectious RNA virus known for its immunosuppressive capabilities, chiefly inflicting rapid damage to the bursa of Fabricius (BF) of chickens. Current clinical control of IBDV infection relies on vaccination. However, the emergence of novel variant IBDV (nVarIBDV) has posed a threat to the poultry industry across the globe, underscoring the great demand for innovative and effective vaccines. Our previous studies have highlighted the critical role of IBDV VP5 as an apoptosis-inducer in host cells. In this study, we engineered IBDV mutants via a reverse genetic system to introduce amino acid mutations in VP5. We found that the mutant IBDV-VP5/3m strain caused reduced host cell mortality, and that strategic mutations in VP5 reduced IBDV replication early after infection, thereby delaying cell death. Furthermore, inoculation of chickens with IBDV-VP5/3m effectively reduced damage to BF and induced neutralizing antibody production comparable to that of parental IBDV WT strain. Importantly, vaccination with IBDV-VP5/3m protected chickens against challenges with nVarIBDV, an emerging IBDV variant strain in China, reducing nVarIBDV loads in BF while alleviating bursal atrophy and splenomegaly, suggesting that IBDV-VP5/3m might serve as a novel vaccine candidate that could be further developed as an effective vaccine for clinical control of IBD. This study provides a new clue to the development of novel and effective vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gao H, Zhang S, Chang H, et al. Generation of a novel attenuated IBDV vaccine strain by mutation of critical amino acids in IBDV VP5. Vaccine. 2024. PMID: 38944579. doi:10.1016/j.vaccine.2024.06.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。